XKRX302440
Market cap3.01bUSD
Dec 20, Last price
55,500.00KRW
1D
1.65%
1Q
2.21%
IPO
-66.67%
Name
SK Bioscience Co Ltd
Chart & Performance
P/E
194.84
P/S
11.77
EPS
284.86
Div Yield, %
0.00%
Shrs. gr., 5y
107.44%
Rev. gr., 5y
33.19%
Revenues
369.51b
-19.10%
Net income
22.32b
-81.77%
CFO
29.35b
P
Earnings
Mar 13, 2025
Profile
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 369,505,556 -19.10% | 456,725,871 -50.84% | 929,000,930 311.77% | |||
Cost of revenue | 338,772,125 | 302,391,700 | 421,706,968 | |||
Unusual Expense (Income) | ||||||
NOPBT | 30,733,431 | 154,334,171 | 507,293,962 | |||
NOPBT Margin | 8.32% | 33.79% | 54.61% | |||
Operating Taxes | (14,990,492) | 19,281,233 | 115,988,904 | |||
Tax Rate | 12.49% | 22.86% | ||||
NOPAT | 45,723,923 | 135,052,939 | 391,305,058 | |||
Net income | 22,317,719 -81.77% | 122,451,950 -65.52% | 355,139,277 979.79% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 397,599 | 2,617,946 | 983,255,829 | |||
BB yield | -0.01% | -0.05% | -5.71% | |||
| Debt | ||||||
Debt current | 8,137,402 | 95,792,981 | 61,958,323 | |||
Long-term debt | 33,009,655 | 47,320,949 | 55,361,146 | |||
Deferred revenue | ||||||
Other long-term liabilities | 527,842 | 2,648,749 | 4,581,298 | |||
Net debt | (1,275,723,547) | (87,318,302) | (6,289,319) | |||
| Cash flow | ||||||
Cash from operating activities | 29,346,361 | (124,958,284) | 536,593,688 | |||
CAPEX | (50,295,489) | (76,489,443) | (44,469,560) | |||
Cash from investing activities | (45,278,721) | 272,646,505 | (1,421,940,285) | |||
Cash from financing activities | (89,582,616) | (19,867,162) | 958,380,287 | |||
FCF | 41,501,495 | 44,335,516 | 359,800,619 | |||
| Balance | ||||||
Cash | 1,274,141,241 | 1,480,805,573 | 1,645,663,315 | |||
Long term investments | 42,729,362 | (1,250,373,341) | (1,522,054,527) | |||
Excess cash | 1,298,395,326 | 207,595,939 | 77,158,742 | |||
Stockholders' equity | 543,399,377 | 581,693,865 | 444,248,085 | |||
Invested Capital | 1,181,557,309 | 1,629,875,111 | 1,522,759,319 | |||
ROIC | 3.25% | 8.57% | 41.84% | |||
ROCE | 1.78% | 8.40% | 31.71% | |||
| EV | ||||||
Common stock shares outstanding | 77,014 | 77,021 | 76,500 | |||
Price | 72,000.00 -2.04% | 73,500.00 -67.33% | 225,000.00 | |||
Market cap | 5,544,987,408 -2.05% | 5,661,079,736 -67.11% | 17,212,500,000 | |||
EV | 4,269,263,861 | 5,573,761,433 | 17,206,210,681 | |||
EBITDA | 65,498,134 | 181,570,580 | 526,069,267 | |||
EV/EBITDA | 65.18 | 30.70 | 32.71 | |||
Interest | 1,398,139 | 2,460,940 | 3,426,927 | |||
Interest/NOPBT | 4.55% | 1.59% | 0.68% | |||